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Extracorporeal membrane oxygenation (ECMO) can be a lifesaving therapy in patients with refractory severe respiratory
failure or cardiac failure. Severe acute respiratory distress syndrome (ARDS) still has a high-mortality rate, but ECMO may
be able to improve the outcome. Use of ECMO for respiratory failure has been increasing since 2009. Initiation of ECMO
for adult ARDS should be considered when conventional therapy cannot maintain adequate oxygenation. ECMO can
stabilize gas exchange and haemodynamic compromise, consequently preventing further hypoxic organ damage.
ECMO is not a treatment for the underlying cause of ARDS. Because ARDS has multiple causes, the diagnosis
should be investigated and treatment should be commenced during ECMO. Since ECMO is a complicated and
high-risk therapy, adequate training in its performance and creation of a referring hospital network are essential.
ECMO transport may be an effective method of transferring patients with severe ARDS.
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HypoxiaIntroduction
Extracorporeal membrane oxygenation (ECMO) can be
employed to salvage patients with refractory severe re-
spiratory failure or cardiac failure. When used for patients
with respiratory disease, it is termed respiratory ECMO.
Acute respiratory distress syndrome (ARDS) is character-
ized by acute widespread pulmonary inflammation due to
various causes such as viral infection, bacterial infection,
trauma, and inhalation of toxic substances. Even in recent
years, severe ARDS has a high-mortality rate [1]. However,
it has been suggested that ECMO can be employed to im-
prove the outcome. Although the first adult respiratory
failure patient treated with ECMO was reported as long
ago as 1972, the number of respiratory ECMO patients
remained small for more than 30 years afterward [2-4].
While use of ECMO has been increasing in recent years,
its indications and clinical management protocols are still
under investigation.* Correspondence: shinhiro@nms.ac.jp
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Principles of ECMO and pathophysiology of ARDS
Principles of respiratory ECMO
ECMO is a form of mechanical assist therapy that employs
an extracorporeal blood circuit including an oxygenator
and a pump. To perform standard respiratory ECMO, two
vascular accesses are established, one for removal of ven-
ous blood and the other for infusion of oxygenated blood.
Blood is drained from a major vein and pumped through a
circuit that includes an oxygenator, which oxygenates the
blood and removes carbon dioxide (CO2), after which the
oxygenated blood is returned via the other cannula. When
blood is returned to the venous side of the circulation, the
procedure is known as veno-venous ECMO (VV ECMO),
which provides gas exchange but cannot give cardiac sup-
port (Figure 1A). When blood is returned to the arterial
side of the circulation, this is called veno-arterial ECMO
(VA ECMO), and it can be employed for both gas ex-
change and cardiac support (Figure 1B). If the patient’s
circulation is stable without high-dose inotrope therapy
and echocardiography does not show right ventricular or
left ventricular failure, VV ECMO should be selected. VA
ECMO is associated with the potential risk of major limb
vessel occlusion by the arterial cannula, as well as arter-
ial embolism and refractory cannula site bleeding. Thel. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Vascular access and cannula position. Panel (A) shows the circulatory kinetics of VV ECMO with drainage from the right internal jugular
vein (RIJV) and infusion to the femoral vein (FV). The oxygenated blood from the infusion cannula (red arrow) is mixed with the venous blood
in the inferior vena cava (IVC) and right atrium (RA). The mixed blood (purple arrow) flows through the lungs to the arterial side. Panel (B) shows the
circulatory kinetics of VA ECMO with drainage from the RIJV and infusion to the femoral artery. The venous blood (blue arrow) flows through the lungs
to the upper body without oxygenating the blood if the lung function is poor. Panel (C) shows the correct position of the draining cannula
tip for VV/VA ECMO with drainage from the RIJV and infusion to the femoral vein/artery as panels (A, B). The tip should be located in the
upper or middle RA to drain blood with a lower O2 saturation from the superior vena cava (SVC). Panel (D) shows the tip locating the lower
position than panel (C), where the blood from the IVC is mostly drained. Because the blood from the IVC contains more oxygen than that from the
SVC, the O2 saturation of the drained blood becomes higher; consequently, the efficiency of oxygenation by ECMO is decreasing. A-Ao
denotes ascending aorta, D-Ao descending aorta, RV right ventricle, and FA femoral artery.
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tients are pulmonary hypertension, cardiac dysfunction
associated with sepsis, and arrhythmia.
Because the main purpose of respiratory ECMO is to
maintain oxygenation of the organs, adequate knowledge
of oxygenation is essential for managing ECMO pa-
tients. It should be noted that “hypoxia” is different from
“hypoxaemia” and that hypoxia should be avoided while
hypoxaemia can be accepted [5]. Hypoxia occurs when
oxygen (O2) delivery is insufficient to satisfy the demand
of the organs [6,7]. The arterial O2 content (CaO2) is
almost directly proportional to arterial O2 saturation
(SaO2) × haemoglobin (Hb). For example, the CaO2 of a
patient with SaO2 of 70% and Hb of 12 g/dl is higher
than that of a patient with SaO2 of 90% and Hb of 9 g/dl.
The latter situation is typical of a patient with anaemia
and is unlikely to result in hypoxia [8]. Actually, hypoxia
may not occur in either situation as long as cardiac output
is preserved.
In addition, we often want to know the amount of O2
supplied by ECMO. If lung function is very poor, then O2
consumption corresponds to the amount of O2 suppliedby ECMO, which is determined as the difference be-
tween returning blood O2 content and draining blood
O2 content multiplied by the ECMO flow rate. Thus, oxy-
gen supply is calculated by the following formulae: ECC
[l/min] × 1.39 [mlO2/gHb] ×Hb [g/dl] × 10 × (outSaO2 −
inSvO2), where ECC is the extracorporeal circuit flow rate,
outSaO2 is the saturation of arterialized blood in the
returning circuit (always 1), and inSvO2 is the saturation
of venous blood in the draining circuit [9]. As pulmonary
oxygenation improves, the amount of O2 supplied by
ECMO decreases, which means that monitoring O2 sup-
plied via ECMO can be used to assess the process of
pulmonary recovery (Figure 2) [9,10]. The formulae
also indicate that the efficiency of oxygenation depends
on the saturation of venous blood in the draining cannula.
Pathophysiology of ARDS
ARDS is characterized by the acute development of bi-
lateral lung infiltration on chest X-ray films or computed
tomography scans and hypoxaemia due to any cause other
than heart failure. Since the concept of ARDS was proposed











Figure 2 Changes of O2 supplied by ECMO. Oxygen supplied by ECMO (VO2 ECMO) is shown in an adult ARDS patient with H1N1 influenza.
The amount of oxygen supplied decreases after the 30th day, indicating recovery of lung function. (Reproduced from Ref. [9]). VO2 ECMO is
calculated as follows: ECC [l/min] × 1.39 [mlO2/gHb] × Hb [g/dl] × 10 × (outSaO2 − inSvO2), where ECC is extracorporeal circuit flow, outSaO2 is the
saturation of arterialized blood in the returning circuit, inSvO2 is the venous blood saturation in the draining circuit, and Hb is the haemoglobin.
The coefficient 1.39 (mlO2/gHb) denotes the O2 content (ml) per 1 g of haemoglobin.
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Society of Intensive Care Medicine in 2011 and represents
the latest consensus [1]. According to this definition, severe
ARDS, which is characterized by a partial pressure of arter-
ial O2/fraction of inspired O2 (PaO2/FIO2) <100 mmHg
despite positive end-expiratory pressure (PEEP) >5 cmH2O,
has a very high-mortality rate (45%).
The early phase of ARDS is characterized by inflam-
matory changes of the alveolar epithelium and exudation
of plasma proteins into the alveoli along with neutrophils,
macrophages, and erythrocytes. Fibrin and plasma pro-
teins form a hyaline membrane on the alveolar walls that
may affect lung compliance and gas exchange in addition
to pulmonary inflammation. The proliferative phase of
ARDS usually develops at 5 to 7 days after its onset and
is characterized by proliferation of type 2 alveolar cells
together with interstitial inflammation [12]. In some pa-
tients, interstitial fibrosis progresses as a result of pro-
longed interstitial inflammation.
While the underlying disease triggers pulmonary inflam-
mation, the use of mechanical ventilation to treat ARDS
may aggravate it. The concept of ventilator-induced lung
injury has been proposed, but its mechanism is still under
discussion, with a high-alveolar pressure or excessive
alveolar expansion being suggested to promote such in-
jury [13,14].
History of adult respiratory ECMO
In 1972, Hill reported the first successful use of ECMO
in an adult respiratory failure patient [2]. A 24-year-old
man underwent emergency surgery for multiple fractures
and aortic rupture due to a traffic accident and developed
ARDS 4 days later. He recovered after being placed on
VA ECMO for 75 h. This report attracted considerableattention to respiratory ECMO, and the first random-
ized controlled trial (RCT) was conducted in the United
States between 1974 and 1977 to investigate ECMO
for ARDS [15]. Patients with severe respiratory failure
(either a PaO2 <50 mmHg for 2 h with FIO2 of 100%
and PEEP >5 cmH2O or a PaO2 <50 mmHg for 12 h
with FIO2 >60% and PEEP >5 cmH2O) were randomized
to an ECMO group or a conventional treatment group.
This study found no difference in 30-day survival (the
primary endpoint) between the two groups, since it was
9.5% with ECMO versus 8.3% with conventional treat-
ment. However, it should be noted that only VA ECMO
was employed and high pressure, high-FIO2 ventilation
was performed during ECMO.
In 1986, Gattinoni reported a single-centre observational
study of low-frequency positive pressure ventilation with
extracorporeal CO2 removal (ECCO2R) that employed
the same entry criteria as the above-mentioned RCT
and achieved a 30-day survival rate of 48.8% [16]. In this
study, the ventilation rate was reduced to a minimum
level, with the aim of avoiding lung damage due to re-
peated expansion and contraction of affected alveoli. To
confirm these findings, Morris conducted a single-centre
RCT, between 1987 and 1991, which enrolled 40 patients
who met the same criteria as in the previous two trials
[17]. The patients were randomized to an ECCO2R group
(n = 21) or a conventional ventilation group (n = 19), and
the ECCO2R group was treated according to the strategy
reported by Gattinoni. There was no significant difference
in 30-day survival, which was 42% in the ECCO2R group
vs. 33% in the conventional ventilation group (P = 0.8).
However, high-pressure ventilation was required in the
ECCO2R group to maintain tidal volume and oxygenation,
and ten patients (48%) from this group developed severe
Table 1 Indication and contraindications of ECMO for
ARDS
Indication Contraindications
Acute reversible lung disease
when conventional therapy
cannot sustain life








ARDS associated with bone
marrow transplantationab
ECMO, extracorporeal membrane oxygenation; ARDS, acute respiratory distress
syndrome; PaO2, arterial partial pressure of oxygen; FiO2, fraction of inspired oxygen
aIf the patient is a candidate for lung transplantation, ECMO can be considered.
bWhile leukaemia is a good indication, ARDS associated with bone marrow
transplantation is different. All of our patients with ARDS after bone marrow
transplantation developed pulmonary fibrosis during ECMO, so we do consider
that ECMO is not suitable for severe ARDS associated with bone marrow
transplantation. The same result has been reported based on the data from
the ELSO registry [52].
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tients (33%). Both of these factors could have had an ad-
verse impact on the outcome in the ECCO2R group.
Due to the negative findings of these RCTs, interest in
adult respiratory ECMO declined around the world. How-
ever, a few departments continued to use adult respiratory
ECMO, and the results gradually improved [18-20]. Peek
conducted the CESAR trial of respiratory ECMO from
2001 to 2004 [21]. This RCT enrolled adult patients with
severe potentially reversible respiratory failure and a Mur-
ray score >3 or a pH <7.2. Patients were excluded if they
had been on aggressive mechanical ventilation for >7 days
before ECMO, if they had bleeding complications in-
compatible with heparinization, or if they had any other
condition incompatible with active treatment. Among
180 eligible patients, 90 each were randomized to an
ECMO group and a conventional ventilation group. In
the ECMO group, 68 patients (75%) actually received
ECMO. The primary endpoint was 6-month survival with-
out severe disabilities, which was achieved in 63% of the
ECMO group compared with 47% of the conventional
ventilation group (relative risk, 0.69; 95% confidence inter-
val, 0.05 to 0.97; P = 0.03). The ECMO circuit used in this
study could provide full oxygenation and thus allowed
lung rest, which was defined as a peak airway pressure
(PIP) of 20–25 cmH2O, PEEP of 10–15 cmH2O, ventila-
tion rate of 10/min, and FIO2 of 0.3.
The H1N1 influenza pandemic occurred in 2009, the
same year as publication of the CESAR trial, and The
Australia and New Zealand Extracorporeal Membrane
Oxygenation (ANZ ECMO) Influenza Investigators
obtained favourable results with ECMO for influenza-
associated ARDS [22]. They reported a survival rate of
71% for patients with a mean age of 34.4 years and
Murray score of 3.8 who were on ventilation for 2 days
before ECMO with a PaO2/FIO2 ratio of 56 mmHg,
PEEP of 18 cmH2O, and PIP of 36 cmH2O. Use of
ECMO during the influenza pandemic achieved varying re-
sults (survival rate: 35%–92%), probably due to differences
in experience with the procedure [9,22-29]. According
to the Extracorporeal Life Support Organization (ELSO)
registry, the average recent survival rate is around 60%–
70% for patients undergoing adult respiratory ECMO [3,4].
Clinical use
Indications
While ECMO can fully replace the function of a patient’s
lungs, there are various possible complications, so its use
needs to be decided by assessing the balance between
benefit and risk [30]. The recent literature suggests that a
PaO2/FIO2 ratio of 70–80 mmHg, Murray score >3, and
pH <7.2 provide a reasonable threshold for considering
ECMO in adults with ARDS (Table 1) [4,21,25]. The ab-
solute contraindications to ECMO are irreversible lungdisease with no indication for lung transplantation and
severe brain damage associated with major cerebral in-
farction or severe intracranial bleeding. We should decide
whether or not to initiate ECMO based on the underlying
disease rather than the comorbidities or the severity of
multi-organ dysfunction. If the diagnosis of such an
underlying disease has not been established, it is rea-
sonable to consider ECMO.However, there is an alter-
native opinion of not initiating ECMO if the outcome is
considered likely to be poor because it is a very expensive
and labour-intensive procedure. Various criteria have been
proposed as “relative contraindications” to ECMO in the
literature and the ELSO guideline, such as immunosuppres-
sion, bleeding, and mechanical ventilation at high settings
(FIO2 >0.9, PIP >30 mmHg) for >7 days [4,18,21,30]. It is
difficult to standardize such criteria because the outcomes
and available resources vary among departments or coun-
tries. While a department that has sufficient staff, financial
resources, and experience might initiate ECMO in patients
with a difficult background, a department possessing less
resources or experience should probably not attempt it.
Cannulation
When performing cannulation, we should consider the
diameter of the cannula and the position of its tip. The
cannula diameter, particularly that of the draining cannula,
restricts the flow rate, so it should be selected to allow
adequate flow. A 23–27 Fr cannula is generally used for
drainage, and a 17–21 Fr cannula is used for infusion.
Low-circuit flow can occur due to incorrect positioning
of the cannula tip. Another problem arises if the blood
in the draining cannula has a high-O2 saturation, reducing
the efficiency of oxygenation by ECMO (see the “Principles
of respiratory ECMO” section). Cannula position should
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because neck positioning and lung recruitment can easily
shift it.
Cannulation for VV ECMO is usually performed with
two single-lumen cannulas or one double-lumen cannula.
If two single-lumen cannulas are employed, two vascular
access points are required, which are usually the right in-
ternal jugular vein (RIJV) and a femoral vein (FV). When
the draining cannula is inserted into the RIJV and the in-
fusion cannula is placed in a FV, the draining cannula tip
should be positioned in the upper or middle right atrium
(RA) (Figure 1A,C). If the tip is positioned in the lower
RA or the inferior vena cava (IVC), it may drain a large
amount of infused oxygenated blood and cause ineffi-
cient oxygenation, which is referred to as “significant
re-circulation” (Figure 1D). On the contrary, when the
draining cannula is inserted into a FV and the infusion
cannula is placed in the RIJV, the draining cannula tip
should be positioned in the IVC. The IVC can collapse
because of hypovolemia or high-abdominal pressure,
and this may lead to drainage problems. The Avalon®
double-lumen cannula, which became available recently,
is always inserted into the RIJV [31]. Its tip should be
placed in the IVC at 6–8 cm below the base of the RA so
that the infusion hole (9.4 cm from the tip) is positioned
in front of the tricuspid valve. Otherwise, blood may be
infused into the hepatic vein or superior vena cava
(SVC), causing congestive liver damage or significant re-
circulation, respectively. Complications such as right ven-
tricular perforation have also been reported [32,33].
VA ECMO should be considered for a patient with
haemodynamic problems. Cannulation is normally achieved
by drainage from the RA via the RIJV or a FV and infusion
into a femoral artery (Figure 1B). In most cases, the heart
continues to pump blood during VA ECMO, which means
that less oxygenated blood from the left ventricle may cir-
culate through the upper body while fully oxygenated blood
from the circuit perfuses the lower body, so that venous O2
saturation may be lower in the SVC than in the IVC. In this
situation, the tip of the draining cannula should be posi-
tioned in the upper or middle RA to drain the less oxygen-
ated venous blood from the SVC (Figure 1C). If the tip is
placed in the lower RA or IVC, the less oxygenated blood
from the SVC may flow through the lungs to the aorta,
which means that the O2 saturation of blood in the coron-
ary or carotid arteries can become significantly low if the
patient’s lung function is poor enough (Figure 1D).
Management
The only additional treatment required during ECMO is
anticoagulation. Management of ECMO patients and or-
dinary intensive care unit (ICU) patients is essentially
based on the same strategy, including minimum sedation,
mobilization, conservative fluid management, and lungprotective ventilation among other points. However, pa-
tients are unstable before ECMO, which means that deep
sedation, paralysis, fluid overload, and high-pressure venti-
lation are common. ECMO can stabilize gas exchange and
alleviate haemodynamic compromise, with minimum
sedation and lung protective ventilation, consequently
avoiding further organ damage.
There is one physiological difference between ECMO
patients and ordinary ICU patients, which is related to
SaO2. Some ECMO patients have virtually no lung func-
tion in the early phase of ARDS, so venous blood passes
through the lungs without oxygenation, making it impos-
sible to maintain the SaO2 above 90% even with ECMO.
Although a high SaO2 is desirable, applying excessive
pressure to the patient’s lungs is not. This is a typical
dilemma that arises during ECMO. How should such
patients be managed? Low SaO2 may not be harmful to
around 70% provided that O2 delivery is preserved by a
normal Hb and normal cardiac output [6,7,34]. Therefore,
tolerating a low SaO2 may be a better solution than in-
creasing the ventilator settings or performing central
cannulation. Lindén reported that patients undergoing
ECMO for severe ARDS remained awake when the SaO2
was as low as 70% and had a survival rate of 76% with-
out long-term sequelae affecting health-related quality
of life [20,35].
The same considerations apply to blood transfusion. Be-
cause of possible complications, routine blood transfusion
should be avoided even for patients with low Hb, except if
they have hypoxia [8,36]. For example, if an ECMO pa-
tient with a SaO2 of 70% and Hb of 9 g/dl develops signs
of hypoxia, transfusion may be a more reasonable solution
than any other intervention. The transfusion threshold
varies among patients, mostly depending on the SaO2 and
O2 consumption. A low-venous-O2 saturation is one of
the clinical features of hypoxia, but symptoms probably
provide the best clue as to whether or not there is a risk of
hypoxic brain damage. If a patient is awake and communi-
cating well, hypoxic brain damage may not occur even
when the SaO2 is around 70% [20].
Ventilation at pressures high enough to damage the
lungs should be avoided during ECMO. According to the
ELSO guideline and CESAR trial, ventilation with a PIP of
less than 25 cmH2O, PEEP of 5–15 cmH2O, and FIO2 of
0.3 is recommended during ECMO [4,21]. On the other
hand, recent ARDS literature has suggested that lung pro-
tection is achieved by ventilation with tidal volume limited
to as little as 6 ml per kilogram of ideal body weight and
PEEP just high enough to keep the lungs open. How-
ever, the effectiveness of this approach has still not been
proven, particularly during ECMO [37,38].
When the clinical state is stabilized after initiation of
ECMO, waking the patient should be attempted. In ICU
patients, the depth of sedation is associated with the
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tality [39], while minimizing sedation may be related to a
satisfactory outcome of ECMO [20]. It is common for
attempted waking to fail during the first few days because
of delirium and agitation. However, the patient usually
starts to adapt to the ventilator and ECMO in the follow-
ing few days. Waking an ECMO patient is worth attempt-
ing because of benefits such as more stable circulation,
stimulation of spontaneous breathing, a larger tidal vol-
ume, and, above all, communication with the staff and
family.
Systemic anticoagulation is necessary during ECMO,
which is usually achieved by infusion of unfractionated
heparin and monitoring of the whole blood activated clot-
ting time and activated partial thromboplastin time. The
ELSO guideline suggests that the target activated clotting
time is between 160 and 200 s and the target activated par-
tial thromboplastin time is 1.5 times normal [4]. These
values may be adjusted if the patient shows a bleeding
tendency or if there is clot formation in the circuit.
Weaning and ceasing treatment
Weaning can be attempted after the patient has improved
sufficiently with reasonable ventilator settings such as
FIO2 <0.4, PIP <25 cmH2O, stable breathing pattern, and
respiration rate <30/min [4]. With VV ECMO, weaning
is achieved by simply turning off the oxygen. With VA
ECMO, the flow rate is usually reduced to 1 l/min.
Echocardiography is useful for accessing cardiac function
or the presence of pulmonary hypertension. If circulation
and gas exchange are stable with reasonable ventilator
settings and low-dose inotropes, we clamp the circuit
for a few minutes. If the patient develops agitation, tach-
ypnea, and hypoxaemia, the attempt at weaning should be
suspended. After weaning, patients tend to need more
fluid infusion, more sedation, higher ventilator settings,
and higher doses of inotropes. If patient deteriorates
markedly after weaning, re-cannulation to start ECMO
again should be considered.
ECMO only buys time for making a diagnosis or to
allow recovery from a life-threatening underlying disease.
If the patient has irreversible lung damage or severe brain
damage with no chance of recovery, cessation of ECMO
should be approved. However, judging an ECMO pa-
tient who is not indicated for lung transplantation to be
“irreversible” is equivalent to a death sentence, so irre-
futable evidence is needed. It may be impossible to make
such a judgement within a few weeks after the onset of
ARDS without a diagnosis. Even detection of fibrosis by
computed tomography or finding pulmonary hypertension
is not convincing evidence of irreversibility. When the
patient does not improve by at least several weeks or
1 month after the onset of ARDS, continuing ECMO
may be considered futile. Lung biopsy can be performedto confirm a diagnosis of pulmonary fibrosis. The period
for which ECMO can be continued is unknown, and there
have been some reports of a successful outcome after
more than 1 month of treatment [10,40].
Complications and training
In ECMO patients, severe bleeding sometimes occurs
after small procedures that are safe for ordinary ICU pa-
tients. Therefore, we should consider whether even small
procedures are required and should prevent bleeding
complications by avoiding unnecessary procedures.
For example, thoracic cavity puncture is usually safe
but may occasionally lead to massive bleeding due to
heparinization for ECMO.
The risk of bacteraemia and fungaemia is also high, be-
cause the blood is always in contact with artificial surfaces
where bacteria and fungi can propagate easily. Cannulas
can allow skin bacteria to enter the blood. There are no
guidelines about prophylactic antibiotics or anti-fungal
treatment for ECMO, but we should pay closer attention
to this issue in ECMO patients than in ordinary ICU pa-
tients [41]. Coagulase-negative Staphylococci and Candida
species are common causes of ECMO-related blood
stream infection [42], and the risk of infection with
Stenotrophomonas maltophilia and Aspergillus species
may be increased in patient on long-term ECMO [43,44].
Circuit problems during ECMO can be fatal. Therefore,
well-trained staffs are required with enough experience to
ensure the safety of ECMO management. Based on data
from the ELSO registry, Brodie reported that the inci-
dence of oxygenator failure is 17.5%, while that of oxy-
genator clotting is 12.2%, other circuit clotting is 17.8%,
cannula-related problems is 8.4%, other mechanical com-
plications is 7.9%, and haemolysis is 6.9% [30].
Adequate staff training is essential for improving the
outcome of ECMO. Water-drill training is simple and
can be performed regularly. Simulation training is more
complicated and expensive, but its effectiveness was
reported recently [45,46]. When the Italian ECMO net-
work was set up rapidly in 2009 because of the H1N1
influenza pandemic, ECMO simulation training was found
to be effective [46]. Animals should not be used for
routine training.
Centralized ECMO and transport
ECMO is a high-risk and complicated therapy required
by a small number of patients. Based on data accumulated
in Paris, Combes reported that ARDS severe enough to
warrant consideration of ECMO may not occur in more
than five to ten cases per million population annually [47].
If all regional hospitals have an ECMO programme, each
centre might only treat a few patients per year, which is
not enough for the staff to maintain competence. Al-
though the acceptable minimum number of patients is
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have suggested at least 20 cases per year are required
[48,49]. To achieve this caseload, it is necessary to develop
a patient transport system and perform ECMO at only
selected centres. The Italian method of centralizing the
management of severe ARDS patients was effective dur-
ing the H1N1 influenza pandemic in 2009, being based
on specific criteria and a practical algorithm from con-
sultation to transport [25].
Because patients who need ECMO are always severely
ill, conventional transport is hazardous. In the CESAR
trial, 81 patients from the ECMO group were transported
on mechanical ventilation and 2 patients died during
transport (2.4%) [21], while a report about ECMO trans-
port indicated that 1 out of 221 patients (0.5%) died
during transport [50]. More than 670 patients have under-
gone ECMO transport by the ECMO Centre Karolinska
transport team since 1996 and only 1 patient has died
(personal data). It is impossible to statistically compare
these results, but ECMO transport may be safer for
ECMO candidates than transport on mechanical venti-
lation [50,51]. Of course, ECMO transport has to be pro-
vided by a well-trained ECMO team, and it should be
available 24 h a day, 7 days a week.Conclusions
ECMO should be considered for patients with ARDS
when they cannot survive with conventional therapy. It
can stabilize gas exchange and haemodynamic comprom-
ise, thus preventing further organ damage. ECMO is not a
treatment for ARDS, and the aetiology of ARDS varies.
Therefore, the underlying disease should be investigated
in each patient and appropriate treatment should be com-
menced while the patient is on ECMO. Because ECMO is
complicated, training in the necessary techniques and
forming a network of hospitals to manage these patients
are essential. ECMO transport may be safer than transport
on ventilation for transferring patients with severe ARDS
to an ECMO management centre.Abbreviations
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